EGFR and non-small cell lung carcinoma: With the conceivable improvement and maturation of CRISPR/Cas technology, combining this molecular surgical approach with traditional surgery, radiation, and/or TKI treatment would have the potential to significantly improve the survival of patients with EGFR‐mutant NSCLC.